Skip to content
Screener

Organon OGN Debt-to-equity

Debt-to-equity at other companies

Pfizer logo
PfizerPFE
0.7×0.0×
Amgen logo
AmgenAMGN
4.9×-2.7×
The Cooper Companies, Inc. logo
The Cooper Companies, Inc.COO
0.4×+0.1×
Biogen logo
BiogenBIIB
0.4×0.0×
AbbVie logo
AbbVieABBV
46.6×+38.6×
Opko Health logo
Opko HealthOPK
0.0×

Other financials

Income statement

See full
Revenue$1.5B-3.5%
Gross profit$783.0M-6.9%
Net income$146.0M+67.8%
EPS (diluted)$0.55+66.7%

Balance sheet

See full
Cash & equivalents$1.1B+104%
Total debt$8.6B-4.3%
Total equity$903.0M+66.6%
Total assets$13.0B-1.2%

Cash flow

See full
Operating cash flow$225.0M+200%
CapEx$37.0M+15.6%
Free cash flow$188.0M+337%

Valuation

See full
Market cap$3.56B+57.0%
Enterprise value$11.01B+4.2%
P/E6.6×+2.1×
P/S0.6×+0.2×

Profitability

See full
Gross margin52.8%-4.4pp
Net margin8%-12.3pp
FCF margin11.1%-1.3pp

Returns & leverage

See full
Return on equity71.6%
Current ratio+0.3×

Where this comes from

Calculated from Organon’s reported figures.

Based on the most recent quarter.

The source filing: Organon’s 10-Q, filed May 4, 2026. Open the filing →

Filed
May 4, 2026, 8:46 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001628280-26-029532

FAQ

What is Organon's debt-to-equity?
Organon (OGN) reported debt-to-equity of 9.5× in Q1 2026.
How has Organon's debt-to-equity changed year-over-year?
Organon's debt-to-equity decreased by 42.6% year-over-year, from 16.5× to 9.5×.
What is the long-term trend for Organon's debt-to-equity?
Over 2 years (2020 to 2025), Organon's debt-to-equity has grown at a 4431.0% compound annual growth rate (CAGR), from 0× to 11.7×.
What does debt-to-equity mean?
Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.

Ask your AI about Organon's debt-to-equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude